Adverum Biotechnologies Inc ADVM.OQ ADVM.O is expected to show no change in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Adverum Biotechnologies Inc is for a loss of $1.94 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Adverum Biotechnologies Inc is $24.00, above its last closing price of $3.49.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -1.36 | -1.96 | Missed | -44.2 | |
Sep. 30 2024 | -1.29 | -1.31 | -1.30 | Beat | 0.5 |
Jun. 30 2024 | -1.44 | -1.47 | -0.89 | Beat | 39.4 |
Mar. 31 2024 | -1.55 | -1.40 | -1.50 | Missed | -6.8 |
Dec. 31 2023 | -3.35 | -3.37 | -2.30 | Beat | 31.7 |
Sep. 30 2023 | -3.06 | -3.15 | -3.30 | Missed | -4.7 |
Jun. 30 2023 | -3.12 | -3.29 | -3.10 | Beat | 5.7 |
Mar. 31 2023 | -3.20 | -3.20 | -2.90 | Beat | 9.5 |
This summary was machine generated May 5 at 11:11 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。